Detalhe da pesquisa
1.
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Cell
; 176(1-2): 334-347.e12, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30580966
2.
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.
Nature
; 598(7882): 682-687, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671158
3.
CD4 T cells and toxicity from immune checkpoint blockade.
Immunol Rev
; 318(1): 96-109, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491734
4.
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Oncologist
; 29(4): e507-e513, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37971411
5.
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.
Mol Cancer
; 22(1): 182, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964379
6.
Determinants of overall survival in patients with metastatic uveal melanoma.
Cancer
; 129(20): 3275-3286, 2023 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37382208
7.
Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.
Ophthalmology
; 130(6): 598-607, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739981
8.
Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma.
Cell Mol Life Sci
; 79(7): 377, 2022 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737114
9.
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Future Oncol
; 16(28): 2165-2175, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32723187
10.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med
; 373(1): 23-34, 2015 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26027431
11.
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
J Am Acad Dermatol
; 79(6): 1081-1088, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30025829
12.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
J Immunol
; 194(3): 950-9, 2015 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25539810
13.
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Lancet Oncol
; 17(7): 976-983, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27267608
14.
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med
; 369(2): 122-33, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724867
15.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 16(4): 375-84, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795410
16.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med
; 366(26): 2443-54, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22658127
17.
Reversing Resistance to Checkpoint Inhibitors and Targeted Therapy in Metastatic Melanoma.
Clin Adv Hematol Oncol
; 18(7): 408-410, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32903252
18.
Programmed death ligand-1 expression in non-small cell lung cancer.
Lab Invest
; 94(1): 107-16, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24217091
19.
Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.
Ophthalmology
; 126(7): 1058-1062, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30735682
20.
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Proc Natl Acad Sci U S A
; 108(40): 16723-8, 2011 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-21933959